Genome-wide investigation of regional blood-based DNA methylation adjusted for complete blood counts implicates BNC2 in ovarian cancer.
Due to its potential as a biomarker for early cancer detection, blood-based DNA methylation (DNAm) is of interest in cancer research. Specifically, highly predictive mechanisms for early detection of epithelial ovarian cancer (EOC) are desired, so previous studies have compared DNAm between EOC cases and controls. However, case-control studies are confounded by the distribution of white blood cell types through an immune response induced by the cancer. Rather than determining the distribution of the cell types manually or investigating isolated cell types, an alternative approach involves the use of complete blood count (CBC), which is routinely collected. In the analysis of an EOC case-control study of DNAm, we incorporate CBC measures to adjust for this confounding and compare DNAm between 242 EOC cases and 181 age-matched controls (assayed on the Illumina Infinium HumanMethylation27 or HumanMethylation450 Beadchips), at both the individual CpG and CpG island levels. We found that adjustment for leukocyte distribution using CBC measurements dramatically reduced confounding, with 62 single CpG sites found to be associated with EOC status after adjustment (P < 5E-8). Additionally, regional DNAm was assessed by applying principal components analysis to CpG islands. The top associated CpG island (P = 7E-6) was located in the promoter/transcription start site of the human basonuclin 2 gene (BNC2), a known susceptibility gene for EOC risk identified through GWAS. Follow-up studies are necessary to establish the role of BNC2 in blood-based DNA and EOC, including prospective studies to validate this region as a potential biomarker and predictor of EOC susceptibility.
Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.
Stacey J
SJ
Winham
Sebastian M
SM
Armasu
Mine S
MS
Cicek
Melissa C
MC
Larson
Julie M
JM
Cunningham
Kimberly R
KR
Kalli
Brooke L
BL
Fridley
Ellen L
EL
Goode
D000293:Adolescent; D000328:Adult; D001772:Blood Cell Count; D000077216:Carcinoma, Ovarian Epithelial; D016022:Case-Control Studies; D018899:CpG Islands / Q000235:genetics*; D004247:DNA / Q000235:genetics / Q000378:metabolism; D019175:DNA Methylation / Q000235:genetics*; D004268:DNA-Binding Proteins / Q000235:genetics*; D044127:Epigenesis, Genetic; D005260:Female; D015894:Genome, Human / Q000235:genetics*; D006801:Humans; D008423:Maternal Age; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000235:genetics*; D009504:Neutrophils / Q000166:cytology; D009928:Organ Specificity; D010051:Ovarian Neoplasms / Q000235:genetics*; D011401:Promoter Regions, Genetic / Q000235:genetics; D024363:Transcription Initiation Site; D055815:Young Adult
C484527:BNC2 protein, human; D004268:DNA-Binding Proteins; D004247:DNA
CpG island; complete blood count; epigenetics; etiology; principal components